Vorapaxar in the secondary prevention of atherothrombosis.
Fairfax, United States. In Expert Rev Cardiovasc Ther, 12 Dec 2015
UNASSIGNED: Dual antiplatelet therapy with aspirin, a platelet cyclooxygenase-1 inhibitor and P2Y12 receptor blockers, remains the major drug strategy to prevent ischemic event occurrence in patients with acute coronary syndromes and in patients undergoing coronary stenting, but there some limitations that can be overcome by targeting novel targets.
Eicosanoid pathway in colorectal cancer: Recent updates.
Ankara, Turkey. In World J Gastroenterol, 07 Dec 2015
Enzymatic metabolism of the 20C polyunsaturated fatty acid (PUFA) arachidonic acid (AA) occurs via the cyclooxygenase (COX) and lipoxygenase (LOX) pathways, and leads to the production of various bioactive lipids termed eicosanoids.
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.
More papers using
Houston, United States. In Nature, Feb 2015
In vivo administration of the cyclooxygenase-2 (COX2) inhibitor celecoxib effectively abolishes a PGE2- and COX2-mediated wound response gene signature, and attenuates progressive manifestation of chemoresistance in xenograft tumours, including primary xenografts derived from a patient who was resistant to chemotherapy.